文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

危重症患者循环中的Gasdermin-D

Circulating Gasdermin-D in Critically Ill Patients.
PubMed 文献 · Crit Care Explor · 2019-09-17
一句话结论前瞻性预试验显示脓毒症危重症患者微粒中可检测到活性Gasdermin-D,而健康志愿者及非脓毒症危重症患者微粒中未见明显水平。

该前瞻性预试验在俄亥俄州立大学医学中心内科ICU开展,比较危重症患者与健康供者微粒中活性Gasdermin-D水平及临床结局。血浆经超速离心分离微粒,免疫印迹鉴定蛋白,ImageJ光密度定量,研究者揭盲后与医生判定的临床诊断和结局比较。健康志愿者及非脓毒症危重症患者微粒中未见明显活性Gasdermin-D,而脓毒症危重症患者微粒中Gasdermin-D水平升高。微粒活性Gasdermin-D与CD63(外泌体标志物)、CD14(单核细胞标志物)、CD69(单核细胞活化标志物)呈显著正相关(R²=0.37,p=0.0011;R²=0.85,p<0.0001;R²=0.43,p=0.0003)。

要点

  • 健康志愿者及非脓毒症危重症患者微粒中未见明显活性Gasdermin-D水平,脓毒症危重症患者微粒中Gasdermin-D水平升高。
  • 微粒活性Gasdermin-D与CD63(外泌体标志物)正相关(R²=0.37,p=0.0011)。
  • 微粒活性Gasdermin-D与CD14(单核细胞标志物)正相关(R²=0.85,p<0.0001)。
  • 微粒活性Gasdermin-D与CD69(单核细胞活化标志物)正相关(R²=0.43,p=0.0003)。
  • 作者认为脓毒症患者活性Gasdermin-D包裹于活化单核细胞来源的外泌体中,需在临床环境中进一步表征。

适用人群与场景

  • 入住俄亥俄州立大学医学中心内科ICU的危重症患者,与健康供者比较。

研究设计与关键结果

  • 前瞻性预试验,比较危重症患者与健康供者微粒中活性Gasdermin-D水平及临床结局。
  • 血浆于知情同意时采集,超速离心分离微粒,免疫印迹鉴定微粒裂解物中的目标蛋白,ImageJ光密度定量。
  • 研究者揭盲后,将微粒活性Gasdermin-D水平与医生判定的临床诊断和结局比较。
  • 健康志愿者及非脓毒症危重症患者微粒中未见明显活性Gasdermin-D水平,脓毒症危重症患者微粒中Gasdermin-D水平升高。
  • 微粒活性Gasdermin-D与CD63正相关(R²=0.37,p=0.0011),与CD14正相关(R²=0.85,p<0.0001),与CD69正相关(R²=0.43,p=0.0003)。

证据类型、等级与局限

  • 证据类型:前瞻性预试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,本研究首次证明ICU脓毒症患者存在循环活性Gasdermin-D,并提示其包裹于活化单核细胞来源的外泌体中。
  • 作者认为,需在临床环境中进一步表征。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

UNLABELLED: The key to further improving outcomes in sepsis lies in understanding and abrogating the dysfunctional immune response that leads to organ failure. Activation of gasdermin-D, a pore-forming protein within the inflammasome cascade, has recently been recognized as the critical step in pyroptosis and organ dysfunction. In this study, we sought to investigate the presence of gasdermin-D in critically ill subjects.

DESIGN SETTING AND PATIENTS: Prospective pilot study comparing microparticulate active gasdermin-D levels in critically ill patients admitted to the medical ICU at The Ohio State University Medical Center to healthy donors and clinical outcomes.

INTERVENTIONS: None.

MEASUREMENTS AND MAIN RESULTS: Plasma was collected from subjects upon consent and microparticles were isolated by ultracentrifugation. Proteins of interest were identified by immunoblot analysis of microparticle lysates. Quantification was accomplished by densitometry using ImageJ software (National Institutes of Health, Bethesda, MD). Investigators were then unblinded and compared microparticulate active gasdermin-D levels to physician adjudicated clinical diagnoses and outcomes. No appreciable levels of active gasdermin-D were observed in microparticles from healthy volunteers and nonseptic critically ill patients. However, elevated levels of gasdermin-D were noted in microparticles from the septic cohort of critically ill patients. Furthermore, a significant positive correlation by linear regression was noted when microparticulate active gasdermin-D levels were compared with microparticulate levels of CD63, an exosomal marker, CD14, a monocyte marker, and CD69, a marker of monocyte activation (R 2 = 0.37, p = 0.0011, R 2 = 0.85, p < 0.0001, and R2 = 0.43, p = 0.0003, respectively).

CONCLUSIONS: This is the first study to demonstrate circulating active gasdermin-D in septic patients in the intensive care setting. Our findings also suggest that active gasdermin-D in septic patients is encapsulated in exosomes derived from activated monocytes. Further characterization in the clinical setting is warranted.

来源:Crit Care Explor,查看原文。版权归原作者所有。

参考来源

  1. Homsy E, Das S, Consiglio P, et al. Circulating Gasdermin-D in Critically Ill Patients. Crit Care Explor. 2019. PMID: 32166281. doi:10.1097/CCE.0000000000000039

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。